Table 1.
Clinical characteristics of breast cancer patients (N = 971), by LRIG1 copy number imbalance status
| Characteristic* | Loss (%) | Normal (%) | Gain (%) | p value |
|---|---|---|---|---|
| No. of patients (n=971) | 86 (8.9) | 847 (87.2) | 38 (3.9) | |
| Median follow-up time (y) | 10.26 | 9.50 | 10.26 | |
| Age at diagnosis (y) | ||||
| Mean (SD) | 52.3 (11.8) | 54.5 (12.7) | 55.6(13.6) | |
| <50 (n=394) | 37 (9.4) | 343 (87.1) | 14 (3.6) | 0.88 |
| ≥50 (n=555) | 48 (8.6) | 485 (87.4) | 22 (4) | |
| Race/ethnicity | ||||
| Non-Hispanic white (n=715) | 55 (7.7) | 633 (88.5) | 27 (3.8) | 0.03 |
| Black (n=125) | 16 (12.8) | 100 (80) | 9 (7.2) | |
| Hispanic (n=123) | 15 (12.2) | 106 (86.2) | 2 (1.6) | |
| ER status | ||||
| Positive (n=666) | 49 (7.4) | 590 (88.6) | 27 (4.1) | 0.07 |
| Negative (n=293) | 35 (11.9) | 248 (84.6) | 10 (3.4) | |
| HER2 status | ||||
| Negative (n=768) | 61 (7.9) | 679 (88.4) | 28 (3.6) | 0.09 |
| Positive (n=203) | 25 (12.3) | 168 (82.8) | 10 (4.9) | |
| HER2/ER status | ||||
| HER2+/ER+ (n=115) | 15 (13.0) | 93 (80.9) | 7 (6.1) | 0.67 |
| HER2+/ER– (n=84) | 9 (10.7) | 72 (85.7) | 3 (3.6) | |
| Pathologic stage | ||||
| I (n=304) | 27 (8.9) | 268 (88.2) | 9 (3) | 0.61 |
| II (n=662) | 58 (8.8) | 575 (86.9) | 29 (4.4) | |
| Nuclear grade† | ||||
| I (n=92) | 9 (9.8) | 81 (88) | 2 (2.2) | 0.11 |
| II (n=477) | 35 (7.3) | 426 (89.3) | 16 (3.4) | |
| III (n=336) | 40 (11.9) | 279 (83) | 17 (5.1) | |
| Tumor size (cm) | ||||
| < 2 (n=566) | 48 (8.5) | 500 (88.3) | 18 (3.2) | 0.30 |
| ≥ 2 (n=369) | 36 (9.8) | 315 (85.4) | 18 (4.9) | |
| Lymph node status | ||||
| Negative (n=565) | 54 (9.6) | 489 (86.5) | 22 (3.9) | 0.74 |
| Positive (n=383) | 31 (8.1) | 338 (88.3) | 14 (3.7) | |
| Tumor subtype# | ||||
| Luminal A (n=373) | 18 (4.8) | 343 (92) | 12 (3.2) | 0.005 |
| Luminal B (n=145) | 14 (9.7) | 125 (86.2) | 6 (4.1) | |
| HER2+ (n=203) | 25 (12.3) | 168 (82.8) | 10 (4.9) | |
| TNBC (n=174) | 24 (13.8) | 144 (82.8) | 6 (3.4) | |
| Radiation therapy | ||||
| Yes (n=410) | 41 (10) | 354 (86.3) | 15 (3.7) | 0.63 |
| No (n=535) | 44 (8.2) | 470 (87.9) | 21 (3.9) | |
| Chemotherapy | ||||
| None (n=480) | 41 (8.5) | 420 (87.5) | 19 (4) | 0.94 |
| Anthracycline (n=323) | 30 (9.3) | 282 (87.3) | 11 (3.4) | |
| Anthracycline/taxane (n=114) | 8 (7) | 101 (88.6) | 5 (4.4) | |
| Endocrine therapy | ||||
| Yes (n=422) | 33 (7.8) | 368 (87.2) | 21 (5) | 0.16 |
| No (n=522) | 51 (9.8) | 456 (87.4) | 15 (2.9) |
Abbreviations: SD, standard deviation; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
*
Numbers do not add up to column totals due to missing values for the individual factors.
#
Tumor subtype was determined using ER, PR, Ki67, and HER2 as defined in Materials and Methods.
†
Nuclear grade was determined by the modified Black’s method.